Anthony Vendetti
Anthony Vendetti is the director of research and senior healthcare analyst at Maxim Group, LLC. Mr. Vendetti has been on Wall Street for more than 20 years and follows the medical device, healthcare information technology and services industries. Prior to joining Maxim Group, he was a senior healthcare analyst at Gruntal, UBS Securities and Ladenburg Thalmann. Mr. Vendetti also worked for three years in the healthcare industry at CIGNA, ultimately as a senior healthcare analyst in the managed care division.
Recent Quotes
"VIVE reported Q1/18 revenue of $3.7M, up 21.6% year over year."
—
Anthony Vendetti, Maxim Group
(5/11/18)
more >
"VIVE's Q4/17 revenue of $5.1M was up 108% year over year."
—
Anthony Vendetti, Maxim Group
(3/16/18)
more >
"The net capital raised is sufficient to fund VIVE through 2019E."
—
Anthony Vendetti, Maxim Group
(2/12/18)
more >
"VIVE's preliminary Q4/17 revenue of ~$5.1M was up 108% YOY."
—
Anthony Vendetti, Maxim Group
(1/4/18)
more >
"We would continue to be buyers of VIVE after an in-line Q3/17."
—
Anthony Vendetti, Maxim Group
(11/9/17)
more >
"VIVE's Q3/17 revenue of approximately $4.1M was up roughly 122% YOY."
—
Anthony Vendetti, Maxim Group
(10/18/17)
more >
"We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019."
—
Anthony Vendetti, Maxim Group
(8/11/17)
more >
"We continue to be buyers of VIVE following its seventh consecutive quarter of double-digit revenue growth driven by a successful launch of the U.S. commercialization coupled with reaffirmed guidance."
—
Anthony Vendetti, Maxim Group
(5/12/17)
more >
